Abstract
Clinical experience with using an aromatase inhibitor to suppress estrogen production during puberty for improvement of growth potential in adolescents with short stature is limited. This report documents treatment of such a patient with a combination of growth hormone and letrozole, a third-generation aromatase inhibitor. Our case demonstrates a favorable outcome on a short-term basis.
MeSH terms
-
Adolescent
-
Aromatase Inhibitors / therapeutic use*
-
Biomarkers / blood
-
Bone Density
-
Drug Therapy, Combination
-
Growth Disorders / blood
-
Growth Disorders / drug therapy*
-
Human Growth Hormone / deficiency*
-
Human Growth Hormone / therapeutic use
-
Humans
-
Insulin-Like Growth Factor I / analysis
-
Letrozole
-
Lipids / blood
-
Male
-
Nitriles / therapeutic use*
-
Testosterone / blood
-
Triazoles / therapeutic use*
Substances
-
Aromatase Inhibitors
-
Biomarkers
-
Lipids
-
Nitriles
-
Triazoles
-
Human Growth Hormone
-
Testosterone
-
Insulin-Like Growth Factor I
-
Letrozole